IASO Biotherapeutics, a clinical-stage biopharmaceutical firm engaged in discovering, developing, and manufacturing innovative medicines, has received 500 million ($73.8 million) in a Series C1 round, the firm announced on Wednesday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
